Formulation development and evaluation of orally disintegrating tablets of doxazosin mesylate

Main Article Content

Shilpa P Chaudhari
Neeraj R Kotian
Mahesh M Bhadgale
Vardhman C Bafna


Doxazosin mesylate has some of the ideal characteristics required for an orally disintegrating tablet. There were some challenges faced during this formulation development. The aims of the present research were to mask the bitter taste
of Doxazosin mesylate and to formulate orally disintegrating tablets of taste masked drug. Taste masking was performed by coating Doxazosin Mesylate with suitable polymer Eudragit powdered E-100 using spray drying technique. The resultant microspheres were then evaluated for thermal analysis, yield, particle size, entrapment efficiency and in vitro taste masking.The tablets were formulated by mixing the taste masked microspheres with different types and concentration of superâ€disintegrants and granulated Mannitol was selected as diluent and compressed using direct compression method. The tablets prepared
were evaluated for weight variation, thickness, hardness, friability, drug content, water content, in vitro disintegration time and in vitro drug release and compared with marketed IR tablet of Doxazosin mesylate.


Download data is not yet available.

Article Details

How to Cite
Chaudhari, S. P., Kotian, N. R., Bhadgale, M. M., & Bafna, V. C. (2014). Formulation development and evaluation of orally disintegrating tablets of doxazosin mesylate. Asian Journal of Pharmaceutics (AJP), 6(4).


Hirani J, Rathod D, Vadalia K. Orally disintegrating tabletsâ€A review.

Tropical J Pharm Res 2009;8:161â€72.

Shukla D, Chakravarty S. Mouth dissolving tablets I: An overview of

formulation technology. Sci Pharm 2009;77:309â€26.

Fitzpatrick JM, Desgrandchamps F. The clinical efficacy and tolerability

of Doxazosin standard and gastrointestinal therapeutic system for

benign prostatic hyperplasia. BJU Int 2005;95:575â€9.

Jacob T. Taste A brief tutorial by Tim Jacob. Available from: http://www. [Last accessed on

Aug 23].

Sohi H, Sultana Y, Khar RK. Taste masking technologies in oral

pharmaceuticals: Recent developments and approaches. Drug DevInd

Pharm 2004;30:429â€48.

Khan S, Katariya P, Nakhat P, Yeole P. Taste masking of ondansetron

hydrochloride by polymer carrier system and formulation of

rapidâ€disintegrating tablets. AAPS Pharmsci Tech 2007;8:Article 46.

Sheshala R, Khan N, Darwis Y. Formulation and Optimization of Orally

Disintegrating Tablets of Sumatriptan Succinate. Chem Pharm Bull

(Tokyo) 2011;59:920â€8.

Bora D, Borude P, Bhise K. Taste masking by Spray drying Technique.

AAPS Pharm Sci Tech 2008;9:1159â€64.

Xu J, Bovet L, Zhao K. Taste masking microspheres for orally

disintegrating tablets. Int J Pharm 2008;359:63â€9.

Bhoyar PK, Biyani DM, Umekar MJ. Formulation and characterization

of patientâ€friendly dosage form of ondansetron hydrochloride. J Young

Pharm 2010;2:240â€6.

Mizumoto T, Tamura T, Kawai H, Itai S. Formulation design of an oral,

fastâ€disintegrating dosage form containing tasteâ€masked particles of

famotidine. Chem Pharm Bull (Tokyo) 2008;56:946â€50.

Rohm GmbH, KG Co. Masking the taste of Fast Disintegrating Tablets.

Drug Delivery and Formulation. Innovations in Pharmaceutical

Technology, 109â€111. Available from: [Last

accessed on 2012 Feb 26].

Kalia A, Khurana S, Bedi N. Formulation and evaluation of Mouth

Dissolving tablets of Oxcarbazepine. Int J Pharm Pharm Sci 2009;1:12â€23.

Toshifusa S, Hideshi S, Kenji H, Kunio I. Studies of rapidly disintegrating tablets inoral cavity using co ground mixtures of Mannitol with Crospovidone. Chem Pharm Bull (Tokyo) 2002;50:193â€8.

Bi Y, Sunada H, Yonezawa Y, Danjo K, Lida K. Preparation and evaluation of compressed tablets rapidly disintegrating in the oral cavity. Chem Pharm Bull (Tokyo) 1996;44:2121â€7.

Patel DM, Patel NM, Shah RR, Joana PD, Baldpate AI. Studies in formulation of or dispersible tablets of rofecoxib. Ind J Pharm Sci 2004;66:621â€5.

Dobetti L. Fast melting tablets: Development and technology. Pharm

Tech (Drug Delivery) 2001:44â€50.